History review
A careful history can include cardiac symptoms, known heart conditions, fainting, seizure history, psychiatric history, substance use, previous adverse reactions, and all prescribed, over-the-counter, and non-prescribed substances.
New Zealand safety context
Medical Risks Summary
An evidence-focused overview of key clinical considerations associated with ibogaine use: cardiac rhythm, medicines and metabolism, screening, monitoring, and adverse-event reporting.
This is general information, not medical or legal advice. Decisions involving ibogaine warrant licensed medical advice and urgent care for immediate symptoms.
01 — heart rhythm
Cardiac risk needs careful attention
Ibogaine has been associated with changes in cardiac electrical activity, including QT prolongation. A prolonged QT interval can increase the risk of a dangerous rhythm disturbance called torsades de pointes, a form of polymorphic ventricular tachycardia described by the torsades de pointes medical reference.
Published clinical literature has documented serious cardiac events in connection with ibogaine exposure. For example, a peer-reviewed review indexed by the U.S. National Library of Medicine discusses reported fatalities and the importance of cardiovascular risk factors and co-exposures.
Risk cannot be reduced to a single factor. Existing heart disease, a personal or family history of abnormal rhythms, low potassium or magnesium, dehydration, and concurrent medicines that affect cardiac conduction can all matter. A normal-feeling baseline does not substitute for an appropriate clinical assessment.
- QT interval: a clinician may consider whether the baseline electrocardiogram and any repeat tracings show concerning change.
- Electrolytes: potassium, magnesium and other abnormalities can increase arrhythmia vulnerability.
- Symptoms: chest pain, fainting, palpitations, severe dizziness, or breathing difficulty require urgent medical assessment.
02 — medicines & metabolism
Interactions can extend beyond the initial dose
Ibogaine is metabolised to noribogaine, an active metabolite that may persist after the initial experience. This matters because physiological effects and interactions may not be confined to a short window. The National Library of Medicine’s ibogaine compound record provides a technical reference for the substance and its pharmacological context.
Medication review is therefore a central safety issue. Medicines that can affect QT interval, serotonin signalling, seizure threshold, liver metabolism, or central nervous system function may create additional concern. Alcohol and other substances can also complicate assessment, particularly where use patterns, withdrawal, or recent dosing are uncertain.
For a wider explanation of legal context alongside risk considerations, the New Zealand ibogaine information overview should be read alongside this page. It is not a substitute for a prescriber or another licensed clinician reviewing an individual’s complete medicine list.
03 — clinical safeguards
01
02
03
What pre-treatment screening and monitoring may involve
This page does not recommend treatment. It outlines the kinds of issues clinicians may need to assess before and during exposure to a substance with recognised cardiac and interaction concerns.
Baseline assessment
Clinical consideration may include vital signs, an electrocardiogram, and laboratory assessment where relevant, including electrolytes and organ function that could influence safety or drug metabolism.
Observed monitoring
Where clinicians are involved, monitoring capacity and a clear escalation plan are material considerations because serious cardiac or neurological deterioration can require immediate response.
Questions about whether a setting has appropriate safeguards are separate from questions of legal status and access. The site’s plain-language topic guides can help readers organise questions, but cannot assess an individual’s medical risk.
A cautious reading
Risk assessment is individual, not a checklist alone
Published evidence and case reports can identify hazards, but they cannot determine what is safe for any one person.
Potential risk is not resolved by a single test, a single source, or an informal assurance.
A licensed clinician is the appropriate person to interpret health history, current medicines, clinical findings, and urgency.
04 — New Zealand systems
Serious adverse events should enter formal reporting pathways
In New Zealand, suspected adverse reactions to medicines can be reported through the Centre for Adverse Reactions Monitoring (CARM). The Medsafe adverse reaction reporting guidance explains the national reporting route and why reports can support medicine safety surveillance.
Immediate safety comes first
Symptoms such as collapse, loss of consciousness, chest pain, seizure, severe shortness of breath, or a sustained irregular heartbeat are emergencies. Call 111 or seek urgent medical care rather than relying on an online information resource or waiting to make a report.
For non-emergency suspected adverse reactions, recording the timing of symptoms, substances taken, medicines, and relevant medical information may assist the treating team and an appropriate reporting process. Further background on the resource’s cautious approach is available in our purpose and sourcing principles.
Common questions
Risk questions worth taking to a clinician
Does this page assess whether ibogaine is suitable for an individual?
No. Individual risk assessment depends on a clinician’s review of medical history, medicines, heart rhythm, laboratory findings, and other factors. This page provides general context only and cannot replace licensed medical advice.
Why does noribogaine matter in an interaction review?
Noribogaine is an active metabolite of ibogaine. Its presence means a safety discussion may need to consider effects and interaction potential beyond the initial dosing period, rather than treating exposure as a brief isolated event.
Where should a serious suspected adverse reaction be reported?
In New Zealand, suspected medicine adverse reactions can be reported through the formal CARM process described by Medsafe. In an emergency, immediate clinical care and emergency services take priority over reporting.
Keep legal status and medical risk separate
Access questions do not answer safety questions. Review the legal checklist with the same care you bring to clinical risk information.